Patents by Inventor Emi Hifumi
Emi Hifumi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220259290Abstract: A method for producing a ? light chain antibody having enzyme activity or improved enzyme activity includes modifying a polynucleotide that encodes a ? light chain antibody having a polypeptide having an amino acid sequence where the 95th amino acid residue from the N-terminal of a variable region by the Kabat classification is a proline residue, to delete or substitute the proline residue and to obtain a polynucleotide that encodes a ? light chain antibody having a polypeptide having an amino acid sequence where the 95th amino acid residue from the N-terminal of a variable region by the Kabat classification is deleted or substituted with an amino acid residue other than a proline residue, and expressing a ? light chain antibody having enzyme activity in an intracellular or extracellular expression system by using an expression vector including the polynucleotide that encodes a ? light chain antibody obtained after modification.Type: ApplicationFiled: July 22, 2020Publication date: August 18, 2022Inventors: Taizo UDA, Emi HIFUMI
-
Patent number: 10633429Abstract: A human antibody ? type light chain complex-containing composition includes a complex in which a human antibody ? type light chain is bound to one or more kinds of metal ions selected from the group consisting of Group 10 elements, Group 11 elements, and Group 12 elements. The human antibody ? type light chain is a dimer, cysteines at C terminals of two human antibody ? type light chains are bound to each other via the metal ion, and 0.1 mol or more of the metal ion is bound per 1 mol of the human antibody ? type light chain.Type: GrantFiled: August 13, 2014Date of Patent: April 28, 2020Assignee: JAPAN SCIENCE AND TECHNOLOGY AGENCYInventors: Taizo Uda, Emi Hifumi
-
Publication number: 20190256576Abstract: A human antibody ? type light chain complex-containing composition includes a complex in which a human antibody ? type light chain is bound to one or more kinds of metal ions selected from the group consisting of Group 10 elements, Group 11 elements, and Group 12 elements. The human antibody ? type light chain is a dimer, cysteines at C terminals of two human antibody ? type light chains are bound to each other via the metal ion, and 0.1 mol or more of the metal ion is bound per 1 mol of the human antibody ? type light chain.Type: ApplicationFiled: August 13, 2014Publication date: August 22, 2019Applicant: JAPAN SCIENCE AND TECHNOLOGY AGENCYInventors: Taizo UDA, Emi Hifumi
-
Patent number: 10040863Abstract: According to the present invention, an anticancer agent is provided that has as an active ingredient thereof a human antibody light chain that demonstrates cytotoxicity against cancer cells and particularly lung cancer cells. The anticancer agent of the present invention primarily comprises: a human antibody ?-type light chain in the form of a dimer in which the variable region is composed of a polypeptide represented by the amino acid sequence of SEQ ID NO: 1, 9 or 13 or an amino acid sequence in which one or a plurality of amino acids have been added, deleted or substituted in these amino acid sequences; or, a human antibody ?-type light chain in the form of a monomer in which the variable region is composed of a polypeptide represented by the amino acid sequence of SEQ ID NO: 19 or an amino acid sequence in which one or a plurality of amino acids have been added, deleted or substituted in the amino acid sequence.Type: GrantFiled: May 27, 2016Date of Patent: August 7, 2018Assignee: JAPAN SCIENCE AND TECHNOLOGY AGENCYInventors: Taizo Uda, Emi Hifumi
-
Publication number: 20160340441Abstract: According to the present invention, an anticancer agent is provided that has as an active ingredient thereof a human antibody light chain that demonstrates cytotoxicity against cancer cells and particularly lung cancer cells. The anticancer agent of the present invention primarily comprises: a human antibody ?-type light chain in the form of a dimer in which the variable region is composed of a polypeptide represented by the amino acid sequence of SEQ ID NO: 1, 9 or 13 or an amino acid sequence in which one or a plurality of amino acids have been added, deleted or substituted in these amino acid sequences; or, a human antibody ?-type light chain in the form of a monomer in which the variable region is composed of a polypeptide represented by the amino acid sequence of SEQ ID NO: 19 or an amino acid sequence in which one or a plurality of amino acids have been added, deleted or substituted in the amino acid sequence.Type: ApplicationFiled: May 27, 2016Publication date: November 24, 2016Applicant: Japan Science and Technology AgencyInventors: Taizo UDA, Emi HIFUMI
-
Patent number: 9365637Abstract: The present invention provides: a novel antiviral agent containing a human antibody ? light chain, a novel human abzyme containing a human antibody ? light chain; a polynucleotide, a vector, and a transformant, encoding a human antibody ? light chain of the above; a primer set for effectively obtaining a human antibody ? light chain having a function as an antiviral agent or abzyme; and a method for producing a polynucleotide and a method for producing a polypeptide, each of which method utilizes the primer set.Type: GrantFiled: February 21, 2011Date of Patent: June 14, 2016Assignee: JAPAN SCIENCE AND TECHNOLOGY AGENCYInventors: Taizo Uda, Emi Hifumi, Akira Nishizono, Mitsue Arakawa
-
Publication number: 20150064203Abstract: According to the present invention, an anticancer agent is provided that has as an active ingredient thereof a human antibody light chain that demonstrates cytotoxicity against cancer cells and particularly lung cancer cells. The anticancer agent of the present invention primarily comprises: a human antibody ?-type light chain in the form of a dimer in which the variable region is composed of a polypeptide represented by the amino acid sequence of SEQ ID NO: 1, 9 or 13 or an amino acid sequence in which one or a plurality of amino acids have been added, deleted or substituted in these amino acid sequences; or, a human antibody ?-type light chain in the form of a monomer in which the variable region is composed of a polypeptide represented by the amino acid sequence of SEQ ID NO: 19 or an amino acid sequence in which one or a plurality of amino acids have been added, deleted or substituted in the amino acid sequence.Type: ApplicationFiled: March 5, 2013Publication date: March 5, 2015Applicant: JAPAN SCIENCE AND TECHNOLOGY AGENCYInventors: Taizo Uda, Emi Hifumi
-
Publication number: 20120322135Abstract: The present invention provides: a novel antiviral agent containing a human antibody ? light chain, a novel human abzyme containing a human antibody ? light chain; a polynucleotide, a vector, and a transformant, each of which relating to the containing a human antibody ? light chain of the above; a primer set for effectively obtaining a human antibody ? light chain having a function as an antiviral agent or abzyme; and a method for producing a polynucleotide and a method for producing a polypeptide, each of which method utilizes the primer set.Type: ApplicationFiled: February 21, 2011Publication date: December 20, 2012Applicant: JAPAN SCIENCE AND TECHNOLOGY AGENCYInventors: Taizo Uda, Emi Hifumi, Akira Nishizono, Mitsue Arakawa
-
Publication number: 20060030015Abstract: A process for producing an antibody enzyme which involves an antibody structure analysis step of confirming the presence of a catalyst triplet residue structure wherein a serine residue, an aspartate residue and a histidine residue or a glutamate residue are located stereostructurally close to each other in the stereostructure of an antibldy anticipated based on its amino acid sequence. Since the above-described catalyst triplet residue structure is a structure specific to an antibody enzyme, an antibody enzyme can be efficiently screened by using the same. Examples of the antibody enzyme as described above include an antibody enzyme against Helicobacter pylori urease and an antibody enzyme against chemokine receptor CCR-5.Type: ApplicationFiled: January 19, 2005Publication date: February 9, 2006Inventors: Taizo Uda, Emi Hifumi
-
Patent number: 5147783Abstract: A monoclonal antibody against human manganese-superoxide dismutase characterized in that it is produced by a cell line which has been obtained by immunization of a mouse with human Mn-SOD and then fusion of lymphocytes obtained from the mouse with mouse myeloma cells, and has high specificity against human Mn-SOD; a method for producing a monoclonal antibody against human Mn-SOD having high specificity against human Mn-SOD, which comprises culturing the cell line obtained by immunization of a mouse with human Mn-SOD and then cell fusion of lymphocytes obtained from the mouse with mouse myeloma cells; a kit for assaying human Mn-SOD, comprising:(a) a monoclonal antibody having very high specific immuno-reactivity against human Mn-SOD; and(b) a reagent of a monoclonal antibody having very high specific immuno-reactivity against human Mn-SOD labelled with an enzyme (enzyme labelled antibody); a method for assaying human Mn-SOD use of the kit; a novel diagnostic method of human epithelial ovarian cancer, which coType: GrantFiled: May 15, 1989Date of Patent: September 15, 1992Assignee: Ube Industries, Ltd.Inventors: Taizo Uda, Yukikatsu Itoh, Tetsuo Kawaguchi, Emi Hifumi, Naoyuki Taniguchi, Keiichiro Suzuki, Mutsuo Ishikawa, Shirou Noji